MetaCap

Heron Therapeutics (HRTX) vs Tonix Pharmaceuticals (TNXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Heron Therapeutics (HRTX) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 76.2% versus a loss of 85.2%. Over five years, HRTX leads with a -97.3% price change compared with -100.0% for TNXP. Heron Therapeutics is the larger company by market cap ($48.0 million vs $46.2 million), about 1.0 times the size, while Tonix Pharmaceuticals is growing revenue faster (+29.8% vs +7.4%).

Heron Therapeutics converts more of its revenue into profit, with a net margin of -13.0% versus -946.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HRTX-76.18%TNXP-85.22%
+47%-22%-92%
Nov 21, 20251 yearNov 20, 2026
HRTX-97.51%TNXP-100.00%
+12%-47%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HRTX versus TNXP key metrics
MetricHRTXTNXP
Share price$0.2525$2.38
Market cap$48.04M$46.25M
1-day change-4.39%-6.67%
YTD return-80.58%-84.76%
1-year return-76.18%-85.22%
5-year return-97.32%-100.00%
EPS (TTM)$-0.11$-12.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$154.90M$13.11M
Revenue growth (YoY)+7.36%+29.85%
Net income (latest FY)$-20.20M$-124.02M
Gross margin73.31%49.34%
Operating margin-1.64%-959.05%
Net margin-13.04%-946.22%
52-week high$1.58$20.56
52-week low$0.2479$2.30
Distance from 52-week high-84.02%-88.42%
Analyst consensusnonestrong_buy
Avg. price target upside+2672.28%+1769.75%
Average volume4.56M838.83K
Shares outstanding190.27M19.43M
Employees128142
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Heron Therapeutics is more profitable, keeping -13.0 cents of every revenue dollar as net income versus -946.2 cents for Tonix Pharmaceuticals.
  • Tonix Pharmaceuticals grew revenue faster in its latest fiscal year (+29.85% vs +7.36%).

About Heron Therapeutics

HRTX stock →

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Tonix Pharmaceuticals

TNXP stock →

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.

Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees

HRTX vs TNXP FAQ

Which is bigger, Heron Therapeutics or Tonix Pharmaceuticals?

Heron Therapeutics (HRTX) is larger, with a market capitalization of $48.04M compared with $46.25M for Tonix Pharmaceuticals (TNXP).

Which stock has performed better over the past year, HRTX or TNXP?

HRTX returned -76.18% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.

Are Heron Therapeutics and Tonix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons